Shearman & Sterling advised International Chemical Investors Group (ICIG) and its subsidiary CordenPharma on the acquisition of the Hospira Boulder high containment API site from Pfizer. The transaction is expected to close in November 2017.
Hospira Boulder produces Active Pharmaceutical Ingredients (APIs) and intermediate products with specialized capabilities in small to medium scale highly potent and cytotoxic API manufacturing. Upon completion, Hospira Boulder will be renamed CordenPharma Boulder.
CordenPharma Group was formed by ICIG in 2006 as a pharmaceutical platform. The acquisition of Hospira Boulder’s pharmaceutical supply business represents a unique opportunity to further strengthen CordenPharma’s leading position as a premier Contract Development and Manufacturing Organization supplier of highly potent & oncology APIs to the pharmaceutical industry.
Shearman & Sterling recently advised ICIG on the acquisition of Sandoz Industrial Products GmbH from Novartis.
The Shearman & Sterling team led by partner Thomas König (Frankfurt-M&A) included partner John Cannon (New York-Compensation, Governance & ERISA); counsels Jason Pratt (New York-Environmental) and Jeffrey Tate (Washington, DC-Tax); and associates Andreas Piepers (New York-M&A) and Aliresa Fatemi (Frankfurt-M&A).